Literature DB >> 27197674

Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients.

Athina Markou1, Martha Zavridou2, Ioanna Sourvinou2, George Yousef3, Sofia Kounelis4, Nikos Malamos4, Vasilis Georgoulias5, Evi Lianidou2.   

Abstract

BACKGROUND: Circulating tumor cells (CTCs) and microRNAs (miRNAs) are important in liquid biopsies in which peripheral blood is used to characterize the evolution of solid tumors. We evaluated the expression levels of miR-21, miR-146a, miR-200c, and miR-210 in CTCs of breast cancer patients with verified metastasis and compared their expression levels in corresponding plasma and primary tumors.
METHODS: Expression levels of the miRNAs were quantified by quantitative reverse transcription PCR (RT-qPCR) in (a) 89 primary breast tumors and 30 noncancerous breast tissues and (b) CTCs and corresponding plasma of 55 patients with metastatic breast cancer and 20 healthy donors. For 30 of these patients, CTCs, corresponding plasma, and primary tumor tissues were available.
RESULTS: In formalin-fixed, paraffin-embedded tissues, these miRNAs were differentially expressed between primary breast tumors and noncancerous breast tissues. miR-21 (P < 0.001) and miR-146a (P = 0.001) were overexpressed, whereas miR-200c (P = 0.004) and miR-210 (P = 0.002) were underexpressed. In multivariate analysis, miR-146a overexpression was significantly [hazard ratio 2.969 (1.231-7.157), P = 0.015] associated with progression-free survival. In peripheral blood, all miRNAs studied were overexpressed in both CTC and corresponding plasma. There was a significant association between miR-21 expression levels in CTCs and plasma for 36 of 55 samples (P = 0.008). In plasma, ROC curve analysis revealed that miR-21, miR-146a, and miR-210 could discriminate patients from healthy individuals.
CONCLUSIONS: Metastasis-related miRNAs are overexpressed in CTCs and corresponding plasma; miR-21 expression levels highly correlate in CTCs and plasma; and miR-21, miR-146a, and miR-210 are valuable plasma biomarkers for discriminating patients from healthy individuals.
© 2016 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27197674     DOI: 10.1373/clinchem.2015.253716

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  20 in total

Review 1.  Emergence of Circulating MicroRNAs in Breast Cancer as Diagnostic and Therapeutic Efficacy Biomarkers.

Authors:  Vaishali Aggarwal; Kumari Priyanka; Hardeep Singh Tuli
Journal:  Mol Diagn Ther       Date:  2020-04       Impact factor: 4.074

Review 2.  [Current progress in research of circulating tumor cells].

Authors:  Qian-Wen Zhao; Bo Situ; Lei Zheng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-10-20

Review 3.  Circulating tumor cells as Trojan Horse for understanding, preventing, and treating cancer: a critical appraisal.

Authors:  Alexios-Fotios A Mentis; Petros D Grivas; Efthimios Dardiotis; Nicholas A Romas; Athanasios G Papavassiliou
Journal:  Cell Mol Life Sci       Date:  2020-04-24       Impact factor: 9.261

Review 4.  PhyloOncology: Understanding cancer through phylogenetic analysis.

Authors:  Jason A Somarelli; Kathryn E Ware; Rumen Kostadinov; Jeffrey M Robinson; Hakima Amri; Mones Abu-Asab; Nicolaas Fourie; Rui Diogo; David Swofford; Jeffrey P Townsend
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2016-10-31       Impact factor: 11.414

5.  CCR7 mediates human breast cancer cell invasion, migration by inducing epithelial-mesenchymal transition and suppressing apoptosis through AKT pathway.

Authors:  Bing Xu; Minjie Zhou; Wencai Qiu; Jueming Ye; Qiming Feng
Journal:  Cancer Med       Date:  2017-04-04       Impact factor: 4.452

Review 6.  Liquid biopsy: a step forward towards precision medicine in urologic malignancies.

Authors:  Ashley Di Meo; Jenni Bartlett; Yufeng Cheng; Maria D Pasic; George M Yousef
Journal:  Mol Cancer       Date:  2017-04-14       Impact factor: 27.401

Review 7.  Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine.

Authors:  Yoon Seok Suh; Jae Young Joung; Sung Han Kim; Ho Kyung Seo; Jinsoo Chung; Kang Hyun Lee
Journal:  Biomed Res Int       Date:  2017-11-05       Impact factor: 3.411

8.  Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.

Authors:  Jeremy T-H Chang; Fan Wang; William Chapin; R Stephanie Huang
Journal:  PLoS One       Date:  2016-12-13       Impact factor: 3.240

9.  Network analysis of microRNAs, genes and their regulation in diffuse and follicular B-cell lymphomas.

Authors:  Oshrat Hershkovitz-Rokah; Polina Geva; Mali Salmon-Divon; Ofer Shpilberg; Stella Liberman-Aronov
Journal:  Oncotarget       Date:  2018-01-05

10.  A proteomic analysis of an in vitro knock-out of miR-200c.

Authors:  Bojan Ljepoja; Jonathan García-Roman; Ann-Katrin Sommer; Thomas Fröhlich; Georg J Arnold; Ernst Wagner; Andreas Roidl
Journal:  Sci Rep       Date:  2018-05-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.